Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine

H. C. Diener, David William Dodick, C. C. Turkel, G. Demos, R. E. Degryse, N. L. Earl, M. F. Brin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and purpose: OnabotulinumtoxinA was effective and well tolerated for prophylaxis of headache in patients with chronic migraine (CM) in two randomized, double-blind, placebo-controlled, phase 3 trials. To further assess the safety and tolerability of onabotulinumtoxinA in CM prophylaxis in adults, the pooled safety data from four double-blind, placebo-controlled trials were analyzed. Methods: The pooled analysis included two phase 2 and two phase 3 double-blind, placebo-controlled trials. The safety population was 2436 patients, 1997 of whom received ≥1 dose of onabotulinumtoxinA. The studies shared similar dosing intervals (approximately 12 weeks) with doses between 75 and 260 U. Safety assessments included adverse events (AEs), physical examination and clinical laboratory tests. Results: OnabotulinumtoxinA was safe and well tolerated, with a low discontinuation rate (3.4%) due to AEs. The majority of patients in this pooled analysis received doses between 150 and 200 U, with an average of 163 U per treatment cycle. Of the 1997 patients who received any onabotulinumtoxinA injections, 1455 patients (72.9%) reported at least one AE. Neck pain (12.6%) was the most common onabotulinumtoxinA-associated AE, followed by muscle weakness (8.0%), musculoskeletal stiffness (6.1%) and eyelid ptosis (4.6%). Serious AEs were infrequent, occurring in 5.4% of patients who received any onabotulinumtoxinA treatment and 3.0% of patients receiving placebo. AEs were consistent with the known tolerability profile of onabotulinumtoxinA. Conclusions: Multiple treatments with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks, and up to five treatment cycles, were well tolerated for the prophylaxis of headache in adults with CM.

Original languageEnglish (US)
Pages (from-to)851-859
Number of pages9
JournalEuropean Journal of Neurology
Volume21
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Migraine Disorders
Safety
Placebos
Therapeutics
Headache
Blepharoptosis
onabotulinumtoxinA
Neck Pain
Muscle Weakness
Physical Examination
Injections
Population

Keywords

  • BOTOX
  • Chronic migraine
  • OnabotulinumtoxinA
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. / Diener, H. C.; Dodick, David William; Turkel, C. C.; Demos, G.; Degryse, R. E.; Earl, N. L.; Brin, M. F.

In: European Journal of Neurology, Vol. 21, No. 6, 2014, p. 851-859.

Research output: Contribution to journalArticle

Diener, H. C. ; Dodick, David William ; Turkel, C. C. ; Demos, G. ; Degryse, R. E. ; Earl, N. L. ; Brin, M. F. / Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. In: European Journal of Neurology. 2014 ; Vol. 21, No. 6. pp. 851-859.
@article{7c6088bc60a742e49ef9d5f58a0471ec,
title = "Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine",
abstract = "Background and purpose: OnabotulinumtoxinA was effective and well tolerated for prophylaxis of headache in patients with chronic migraine (CM) in two randomized, double-blind, placebo-controlled, phase 3 trials. To further assess the safety and tolerability of onabotulinumtoxinA in CM prophylaxis in adults, the pooled safety data from four double-blind, placebo-controlled trials were analyzed. Methods: The pooled analysis included two phase 2 and two phase 3 double-blind, placebo-controlled trials. The safety population was 2436 patients, 1997 of whom received ≥1 dose of onabotulinumtoxinA. The studies shared similar dosing intervals (approximately 12 weeks) with doses between 75 and 260 U. Safety assessments included adverse events (AEs), physical examination and clinical laboratory tests. Results: OnabotulinumtoxinA was safe and well tolerated, with a low discontinuation rate (3.4{\%}) due to AEs. The majority of patients in this pooled analysis received doses between 150 and 200 U, with an average of 163 U per treatment cycle. Of the 1997 patients who received any onabotulinumtoxinA injections, 1455 patients (72.9{\%}) reported at least one AE. Neck pain (12.6{\%}) was the most common onabotulinumtoxinA-associated AE, followed by muscle weakness (8.0{\%}), musculoskeletal stiffness (6.1{\%}) and eyelid ptosis (4.6{\%}). Serious AEs were infrequent, occurring in 5.4{\%} of patients who received any onabotulinumtoxinA treatment and 3.0{\%} of patients receiving placebo. AEs were consistent with the known tolerability profile of onabotulinumtoxinA. Conclusions: Multiple treatments with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks, and up to five treatment cycles, were well tolerated for the prophylaxis of headache in adults with CM.",
keywords = "BOTOX, Chronic migraine, OnabotulinumtoxinA, Safety, Tolerability",
author = "Diener, {H. C.} and Dodick, {David William} and Turkel, {C. C.} and G. Demos and Degryse, {R. E.} and Earl, {N. L.} and Brin, {M. F.}",
year = "2014",
doi = "10.1111/ene.12393",
language = "English (US)",
volume = "21",
pages = "851--859",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine

AU - Diener, H. C.

AU - Dodick, David William

AU - Turkel, C. C.

AU - Demos, G.

AU - Degryse, R. E.

AU - Earl, N. L.

AU - Brin, M. F.

PY - 2014

Y1 - 2014

N2 - Background and purpose: OnabotulinumtoxinA was effective and well tolerated for prophylaxis of headache in patients with chronic migraine (CM) in two randomized, double-blind, placebo-controlled, phase 3 trials. To further assess the safety and tolerability of onabotulinumtoxinA in CM prophylaxis in adults, the pooled safety data from four double-blind, placebo-controlled trials were analyzed. Methods: The pooled analysis included two phase 2 and two phase 3 double-blind, placebo-controlled trials. The safety population was 2436 patients, 1997 of whom received ≥1 dose of onabotulinumtoxinA. The studies shared similar dosing intervals (approximately 12 weeks) with doses between 75 and 260 U. Safety assessments included adverse events (AEs), physical examination and clinical laboratory tests. Results: OnabotulinumtoxinA was safe and well tolerated, with a low discontinuation rate (3.4%) due to AEs. The majority of patients in this pooled analysis received doses between 150 and 200 U, with an average of 163 U per treatment cycle. Of the 1997 patients who received any onabotulinumtoxinA injections, 1455 patients (72.9%) reported at least one AE. Neck pain (12.6%) was the most common onabotulinumtoxinA-associated AE, followed by muscle weakness (8.0%), musculoskeletal stiffness (6.1%) and eyelid ptosis (4.6%). Serious AEs were infrequent, occurring in 5.4% of patients who received any onabotulinumtoxinA treatment and 3.0% of patients receiving placebo. AEs were consistent with the known tolerability profile of onabotulinumtoxinA. Conclusions: Multiple treatments with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks, and up to five treatment cycles, were well tolerated for the prophylaxis of headache in adults with CM.

AB - Background and purpose: OnabotulinumtoxinA was effective and well tolerated for prophylaxis of headache in patients with chronic migraine (CM) in two randomized, double-blind, placebo-controlled, phase 3 trials. To further assess the safety and tolerability of onabotulinumtoxinA in CM prophylaxis in adults, the pooled safety data from four double-blind, placebo-controlled trials were analyzed. Methods: The pooled analysis included two phase 2 and two phase 3 double-blind, placebo-controlled trials. The safety population was 2436 patients, 1997 of whom received ≥1 dose of onabotulinumtoxinA. The studies shared similar dosing intervals (approximately 12 weeks) with doses between 75 and 260 U. Safety assessments included adverse events (AEs), physical examination and clinical laboratory tests. Results: OnabotulinumtoxinA was safe and well tolerated, with a low discontinuation rate (3.4%) due to AEs. The majority of patients in this pooled analysis received doses between 150 and 200 U, with an average of 163 U per treatment cycle. Of the 1997 patients who received any onabotulinumtoxinA injections, 1455 patients (72.9%) reported at least one AE. Neck pain (12.6%) was the most common onabotulinumtoxinA-associated AE, followed by muscle weakness (8.0%), musculoskeletal stiffness (6.1%) and eyelid ptosis (4.6%). Serious AEs were infrequent, occurring in 5.4% of patients who received any onabotulinumtoxinA treatment and 3.0% of patients receiving placebo. AEs were consistent with the known tolerability profile of onabotulinumtoxinA. Conclusions: Multiple treatments with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks, and up to five treatment cycles, were well tolerated for the prophylaxis of headache in adults with CM.

KW - BOTOX

KW - Chronic migraine

KW - OnabotulinumtoxinA

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84899992580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899992580&partnerID=8YFLogxK

U2 - 10.1111/ene.12393

DO - 10.1111/ene.12393

M3 - Article

C2 - 24628923

AN - SCOPUS:84899992580

VL - 21

SP - 851

EP - 859

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 6

ER -